Table 2.
Associations between CYP11B2 (-344T/C) gene polymorphism and antihypertensive response to valsartan
| CC+CT (n=65) | TT (n=33) | P | |
|---|---|---|---|
| CSBP (mmHg) | 149.58±12.38 | 146.56±13.48 | P>0.05 |
| CDBP (mmHg) | 95.42±8.50 | 96.50±7.38 | P>0.05 |
| cMAP (mmHg) | 113.47±8.81 | 113.19±8.24 | P>0.05 |
| 24 h SBP (mmHg) | 137.60±11.44 | 135.27±11.86 | P>0.05 |
| 24 h DBP (mmHg) | 83.47±7.73 | 84.45±6.71 | P>0.05 |
| 24 h MAP (mmHg) | 101.52±8.24 | 101.39±7.60 | P>0.05 |
| ΔcSBP(mmHg) | 16.38±8.37 | 11.65±5.10 | P<0.01 |
| ΔcDBP (mmHg) | 9.69±4.76 | 6.35±4.85 | P<0.01 |
| ΔcMAP (mmHg) | 11.92±4.85 | 8.12±4.25 | P<0.01 |
| Δ24 h SBP (mmHg) | 14.80±7.19 | 10.40±4.29 | P<0.01 |
| Δ24 h DBP (mmHg) | 6.19±4.62 | 4.04±3.50 | P<0.05 |
| Δ24 h MAP (mmHg) | 9.06±3.88 | 6.16±2.52 | P<0.01 |
ΔBP: The descending values of the blood pressure after therapy.